ProQR Therapeutics Q4 Net Loss Of €8.9 Million Reinforces Profitability Concerns

Simply Wall St.03-14

ProQR Therapeutics (NasdaqCM:PRQR) has wrapped up FY 2025 with fourth quarter revenue of €4.7 million and a basic EPS loss of €0.08, alongside a net income loss of €8.9 million. These figures put hard...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619714689?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-14 06:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619714689","market":"nz","top_or_hot":-1,"title":"ProQR Therapeutics Q4 Net Loss Of €8.9 Million Reinforces Profitability Concerns","media":"Simply Wall St.","content":"<div>\n<p>ProQR Therapeutics (NasdaqCM:PRQR) has wrapped up FY 2025 with fourth quarter revenue of €4.7 million and a basic EPS loss of €0.08, alongside a net income loss of €8.9 million. These figures put hard...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prqr/proqr-therapeutics/news/proqr-therapeutics-q4-net-loss-of-89-million-reinforces-prof\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProQR Therapeutics Q4 Net Loss Of €8.9 Million Reinforces Profitability Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProQR Therapeutics Q4 Net Loss Of €8.9 Million Reinforces Profitability Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-14 06:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prqr/proqr-therapeutics/news/proqr-therapeutics-q4-net-loss-of-89-million-reinforces-prof><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ProQR Therapeutics (NasdaqCM:PRQR) has wrapped up FY 2025 with fourth quarter revenue of €4.7 million and a basic EPS loss of €0.08, alongside a net income loss of €8.9 million. These figures put hard...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prqr/proqr-therapeutics/news/proqr-therapeutics-q4-net-loss-of-89-million-reinforces-prof\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prqr/proqr-therapeutics/news/proqr-therapeutics-q4-net-loss-of-89-million-reinforces-prof","article_id":"2619714689","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prqr/proqr-therapeutics/news/proqr-therapeutics-q4-net-loss-of-89-million-reinforces-prof","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619714689","pubTimestamp":1773441090,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"ProQR Therapeutics (NasdaqCM:PRQR) has wrapped up FY 2025 with fourth quarter revenue of €4.7 million and a basic EPS loss of €0.08, alongside a net income loss of €8.9 million. These figures put hard numbers around where the business stands today. Over recent periods the company has seen quarterly revenue range from €2.9 million to €4.7 million, while quarterly basic EPS has moved between a loss of €0.12 and a loss of €0.08. As a result, the story for investors remains centered on how...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","PRQR":"ProQR Therapeutics N.V.","BK4007":"制药","BK4539":"次新股"},"translate_title":"ProQR Therapeutics第四季度净亏损890万欧元加剧了盈利能力担忧","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"PRQR":0.9},"content_text":"ProQR Therapeutics (NasdaqCM:PRQR) has wrapped up FY 2025 with fourth quarter revenue of €4.7 million and a basic EPS loss of €0.08, alongside a net income loss of €8.9 million. These figures put hard numbers around where the business stands today. Over recent periods the company has seen quarterly revenue range from €2.9 million to €4.7 million, while quarterly basic EPS has moved between a loss of €0.12 and a loss of €0.08. As a result, the story for investors remains centered on how quickly those losses can narrow from here. For now, the results keep the focus firmly on margins and the trade off between funding growth and moving the business closer to break even. See our full analysis for ProQR Therapeutics. With the latest figures on the table, the next step is to see how this earnings profile lines up against the main narratives around ProQR, from high growth potential to ongoing profitability risks. Curious how numbers become stories that shape markets? Explore Community Narratives NasdaqCM:PRQR Revenue & Expenses Breakdown as at Mar 2026 AdvertisementLosses Stack Up On €42.2 Million LTM Net Income  On a trailing 12 month view to FY 2025, ProQR booked €16.3 million in revenue against a net income loss of €42.2 million and a basic EPS loss of €0.40, so the business is still firmly in loss making mode even as it generates mid teen millions of revenue. Critics highlight the bearish point that forecasts still show ProQR remaining unprofitable over the next three years, and the trailing 12 month loss of €42.2 million helps explain that view, \n     Over the same trailing period, basic EPS sits at a loss of €0.40, which lines up with the idea that earnings are still some distance from break even. Bears also point to the pattern of quarterly net income losses between €8.9 million and €12.2 million in FY 2025 as evidence that, for now, ProQR is running a business model that requires continued funding to support operations.    Revenue Forecast Around 46% Growth Tests Bull Hopes  Revenue is described as being forecast to grow about 46.4% per year off the trailing 12 month base of €16.3 million, so the topline story is framed around relatively fast expected growth starting from a modest revenue level. Supporters lean on a bullish angle that strong forecast revenue growth can eventually help absorb current losses, yet the current trailing loss of €42.2 million shows how much work that growth needs to do, \n     Trailing 12 month revenue of €16.3 million is still well below the size of the trailing 12 month net loss, so even rapid growth would need time before it could materially close that gap. The fact that quarterly revenue in FY 2025 has ranged between €2.9 million and €4.7 million suggests investors may watch closely whether reported figures start to move consistently higher against that 46.4% forecast.    On these numbers, bulls see a growth story trying to outrun sizeable losses, while bears focus on how long that balance might take to shift. 📊 Read the what the Community is saying about ProQR Therapeutics. DCF Fair Value And P/S Gap Versus €1.82 Share Price  The shares trade at €1.82 alongside a cited DCF fair value of about €8.50 and a P/S of 10.3x, compared with 34.9x for peers and 11.6x for the broader biotech industry, which puts ProQR on a lower revenue multiple than both the peer set and the industry in this snapshot. What stands out for a bullish narrative is that the roughly 78.6% discount to the €8.50 DCF fair value and the lower 10.3x P/S ratio both point to a market price that is materially below these reference points, while the trailing 12 month loss of €42.2 million and the expectation of continued unprofitability show why some investors may still hesitate, \n     The combination of a €1.82 share price and a 10.3x P/S ratio is paired with forecasts that ProQR is not expected to reach profitability within three years, which can limit how much weight investors place on the apparent discount. At the same time, the lower P/S versus the 34.9x peer average and 11.6x industry level offers quantified support for bulls who argue that, if revenue grows in line with the 46.4% forecast, there could be room for a re rating against these benchmarks.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on ProQR Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. Reading this, you can see both the hopes and the concerns around ProQR. Act while the details are fresh and weigh the trade offs yourself, including 3 key rewards and 1 important warning sign. See What Else Is Out There ProQR is still carrying sizeable losses against €16.3 million of revenue, with forecasts indicating it may remain unprofitable for at least the next three years. If you want ideas that put more emphasis on financial resilience and potentially steadier compounding, take a look at our 69 resilient stocks with low risk scores right now and compare how those businesses stack up against this profile.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619714689","isCrawlerRequest":true}